GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Shiller PE Ratio

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Shiller PE Ratio : (As of May. 13, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Progenics Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Progenics Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Shiller PE Ratio Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Progenics Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Progenics Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progenics Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Shiller PE Ratio falls into.



Progenics Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Progenics Pharmaceuticals's E10 for the quarter that ended in Mar. 2020 is calculated as:

For example, Progenics Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2020 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2020 (Change)*Current CPI (Mar. 2020)
=-0.19/108.9015*108.9015
=-0.190

Current CPI (Mar. 2020) = 108.9015.

Progenics Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201006 -0.470 91.962 -0.557
201009 -0.520 92.162 -0.614
201012 -0.570 92.474 -0.671
201103 -0.690 94.283 -0.797
201106 1.640 95.235 1.875
201109 -0.340 95.727 -0.387
201112 -0.320 95.213 -0.366
201203 -0.390 96.783 -0.439
201206 -0.320 96.819 -0.360
201209 -0.330 97.633 -0.368
201212 0.020 96.871 0.022
201303 -0.220 98.209 -0.244
201306 -0.240 98.518 -0.265
201309 -0.170 98.790 -0.187
201312 -0.130 98.326 -0.144
201403 -0.150 99.695 -0.164
201406 -0.160 100.560 -0.173
201409 0.510 100.428 0.553
201412 -0.180 99.070 -0.198
201503 -0.150 99.621 -0.164
201506 -0.170 100.684 -0.184
201509 -0.140 100.392 -0.152
201512 -0.100 99.792 -0.109
201603 -0.180 100.470 -0.195
201606 -0.080 101.688 -0.086
201609 0.520 101.861 0.556
201612 -0.100 101.863 -0.107
201703 -0.230 102.862 -0.244
201706 -0.240 103.349 -0.253
201709 -0.220 104.136 -0.230
201712 -0.040 104.011 -0.042
201803 -0.190 105.290 -0.197
201806 -0.200 106.317 -0.205
201809 -0.300 106.507 -0.307
201812 -0.170 105.998 -0.175
201903 -0.220 107.251 -0.223
201906 -0.230 108.070 -0.232
201909 -0.220 108.329 -0.221
201912 -0.130 108.420 -0.131
202003 -0.190 108.902 -0.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Progenics Pharmaceuticals  (NAS:PGNX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Progenics Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.
Executives
Asha Das officer: Chief Medical Officer C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman 10 percent owner, other: See Explanation of Responses FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria 10 percent owner, other: See Explanation of Responses 1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams director
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Headlines

From GuruFocus

Progenics Sends Letter to Shareholders

By Marketwired Marketwired 10-21-2019

Progenics Sends Letter to Shareholders

By Marketwired Marketwired 10-10-2019